Fig. 6From: Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trialsAdverse events comparative risk in patients treated with Palbociclib in all the Paloma trials (Paloma1/TRIO-18, Paloma2 and Paloma3)Back to article page